252 related articles for article (PubMed ID: 35100078)
1. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in catalysis and inhibition of the Jumonji histone demethylases.
Sarah L; Fujimori DG
Curr Opin Struct Biol; 2023 Dec; 83():102707. PubMed ID: 37832177
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
4. JmjC Family of Histone Demethylases Form Nuclear Condensates.
Vicioso-Mantis M; Aguirre S; Martínez-Balbás MA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887017
[TBL] [Abstract][Full Text] [Related]
5. Taking Me away: the function of phosphorylation on histone lysine demethylases.
Karakatsanis NM; Hamey JJ; Wilkins MR
Trends Biochem Sci; 2024 Mar; 49(3):257-276. PubMed ID: 38233282
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Enzyme Assays for JmjC-Domain-Containing Lysine Histone Demethylases (JmjC-KDMs).
Tarhonskaya H; Tumber A; Kawamura A; Schofield CJ
Curr Protoc Pharmacol; 2018 Mar; 80(1):3.15.1-3.15.12. PubMed ID: 30040204
[TBL] [Abstract][Full Text] [Related]
7. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
He X; Zhang H; Zhang Y; Ye Y; Wang S; Bai R; Xie T; Ye XY
Eur J Med Chem; 2022 Mar; 231():114143. PubMed ID: 35101649
[TBL] [Abstract][Full Text] [Related]
8. Jumonji histone demethylases as emerging therapeutic targets.
Park SY; Park JW; Chun YS
Pharmacol Res; 2016 Mar; 105():146-51. PubMed ID: 26816087
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
10. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
11. Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy.
Zhang L; Chen Y; Li Z; Lin C; Zhang T; Wang G
Drug Discov Today; 2023 May; 28(5):103519. PubMed ID: 36754142
[TBL] [Abstract][Full Text] [Related]
12. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
Lee J; Kim JS; Cho HI; Jo SR; Jang YK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
[TBL] [Abstract][Full Text] [Related]
13. The role of histone H3 lysine demethylases in glioblastoma.
Young D; Guha C; Sidoli S
Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
[TBL] [Abstract][Full Text] [Related]
14. [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].
Fu X; Yu G; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1822-1831. PubMed ID: 36651250
[TBL] [Abstract][Full Text] [Related]
15. Histone lysine demethylases in breast cancer.
Paolicchi E; Crea F; Farrar WL; Green JE; Danesi R
Crit Rev Oncol Hematol; 2013 May; 86(2):97-103. PubMed ID: 23266085
[TBL] [Abstract][Full Text] [Related]
16. The role and prospect of lysine-specific demethylases in cancer chemoresistance.
Song YQ; Yang GJ; Ma DL; Wang W; Leung CH
Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609
[TBL] [Abstract][Full Text] [Related]
17. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
Duan L; Perez RE; Chastain PD; Mathew MT; Bijukumar DR; Maki CG
Oncogene; 2019 Jul; 38(28):5643-5657. PubMed ID: 30967636
[TBL] [Abstract][Full Text] [Related]
18. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.
Luo X; Liu Y; Kubicek S; Myllyharju J; Tumber A; Ng S; Che KH; Podoll J; Heightman TD; Oppermann U; Schreiber SL; Wang X
J Am Chem Soc; 2011 Jun; 133(24):9451-6. PubMed ID: 21585201
[TBL] [Abstract][Full Text] [Related]
19. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
[TBL] [Abstract][Full Text] [Related]
20. A scintillation proximity assay for histone demethylases.
Yu W; Eram MS; Hajian T; Szykowska A; Burgess-Brown N; Vedadi M; Brown PJ
Anal Biochem; 2014 Oct; 463():54-60. PubMed ID: 25010373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
